ACET · Adicet Bio Inc. Common Stock
View on chartInsiders & Stakes
| RA CAPITAL MANAGEMENT, L.P. Director | ▼ Sell | Other | 932,624 Shares held | 4/27/2026 | View profile |
| Lloyd Klickstein | ▲ Buy | Grant | 108,566 Shares held | 6/11/2025 | View profile |
| Galimi Francesco SVP & Chief Medical Officer | ▲ Buy | Grant | 101,801 Shares held | 1/24/2024 | View profile |
| Steve Dubin Director | ▲ Buy | Grant | 22,700 Shares held | 6/11/2025 | View profile |
| Jeffrey Chodakewitz Director | ▲ Buy | Grant | 17,700 Shares held | 6/11/2025 | View profile |
| Andrew Sinclair Director | ▲ Buy | Grant | 17,700 Shares held | 6/11/2025 | View profile |
| Katie Peng | ▲ Buy | Grant | 11,800 Shares held | 6/11/2025 | View profile |
| Carl L. Gordon Director | ▲ Buy | Grant | 11,800 Shares held | 6/5/2024 | View profile |
| Jakobovits Aya Director | ▲ Buy | Grant | 11,800 Shares held | 6/5/2024 | View profile |
| Chen Schor President & CEO | ▼ Sell | Tax Withholding | 6,820 Shares held | 1/24/2026 | View profile |
| Michael Kauffman Director | ▼ Sell | Open Market | 5,900 Shares held | 6/5/2024 | View profile |
| Sanna Bastiano EVP, Cell & Genetic Therapies | ▲ Buy | Grant | 5,900 Shares held | 6/1/2023 | View profile |
| Brian Nicholas Harvey Chief Financial Officer | ▼ Sell | Tax Withholding | 5,145 Shares held | 1/24/2026 | View profile |
| Don Healey Chief Technology Officer | ▼ Sell | Tax Withholding | 3,452 Shares held | 1/24/2026 | View profile |
| Blake Aftab Chief Scientific Officer | ▼ Sell | Tax Withholding | 2,981 Shares held | 1/24/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▼ Sell | Open Market | 0 Shares held | 4/8/2026 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 250,000 | — | 4/27/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 40,416 | $264K | 4/8/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 32,523 | $205K | 4/8/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 29,319 | $191K | 4/7/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 2,400 | $15K | 4/7/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 74,751 | $543K | 2/20/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 74,268 | $535K | 2/19/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 74,577 | $525K | 2/18/2026 |
| Blake Aftab | ▼ Sell | Tax Withholding | 535 | $5K | 1/24/2026 |
| Don Healey | ▼ Sell | Tax Withholding | 535 | $5K | 1/24/2026 |
| Chen Schor | ▼ Sell | Tax Withholding | 1,755 | $15K | 1/24/2026 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 546 | $5K | 1/24/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,500,000 | $1.5M | 10/8/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 3,500,000 | $3.5M | 10/8/2025 |
| Jeffrey Chodakewitz | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 |
| Steve Dubin | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 |
| Katie Peng | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 |
| Andrew Sinclair | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 |
| Lloyd Klickstein | ▲ Buy | Grant | 5,900 | $0 | 6/11/2025 |
| Chen Schor | ▼ Sell | Tax Withholding | 28,101 | $26K | 1/24/2025 |
| Don Healey | ▼ Sell | Tax Withholding | 8,560 | $8K | 1/24/2025 |
| Blake Aftab | ▼ Sell | Tax Withholding | 6,270 | $6K | 1/24/2025 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 8,752 | $8K | 1/24/2025 |
| Katie Peng | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Carl L. Gordon | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Jakobovits Aya | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Michael Kauffman | ▼ Sell | Open Market | 5,900 | $8K | 6/5/2024 |
| Andrew Sinclair | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Michael Kauffman | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Steve Dubin | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| Jeffrey Chodakewitz | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,841,100 | $4.4M | 1/25/2024 |
| Carl L. Gordon | ▲ Buy | Open Market | 1,841,100 | $4.4M | 1/25/2024 |
| Carl L. Gordon | ▲ Buy | Open Market | 1,041,700 | $2.5M | 1/25/2024 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,041,700 | $2.5M | 1/25/2024 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 242,200 | $581K | 1/25/2024 |
| Carl L. Gordon | ▲ Buy | Open Market | 242,200 | $581K | 1/25/2024 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 4,957 | $12K | 1/24/2024 |
| Galimi Francesco | ▲ Buy | Grant | 26,300 | $0 | 1/24/2024 |
| Blake Aftab | ▼ Sell | Tax Withholding | 3,565 | $9K | 1/24/2024 |
| Blake Aftab | ▲ Buy | Grant | 19,700 | $0 | 1/24/2024 |
| Don Healey | ▼ Sell | Tax Withholding | 4,870 | $12K | 1/24/2024 |
| Don Healey | ▲ Buy | Grant | 19,700 | $0 | 1/24/2024 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 4,320 | $10K | 1/24/2024 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 26,300 | $0 | 1/24/2024 |
| Chen Schor | ▼ Sell | Tax Withholding | 15,290 | $37K | 1/24/2024 |
| Chen Schor | ▲ Buy | Grant | 70,300 | $0 | 1/24/2024 |
| Blake Aftab | ▼ Sell | Tax Withholding | 7,933 | $11K | 10/12/2023 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 8,093 | $11K | 10/2/2023 |
| Don Healey | ▼ Sell | Tax Withholding | 9,069 | $12K | 10/2/2023 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 7,096 | $10K | 10/2/2023 |
| Chen Schor | ▲ Buy | Open Market | 5,500 | $7K | 10/2/2023 |
| Chen Schor | ▼ Sell | Tax Withholding | 23,208 | $32K | 10/2/2023 |
| Chen Schor | ▼ Sell | Open Market | 5,500 | $7K | 9/29/2023 |
| Chen Schor | ▼ Sell | Open Market | 5,500 | $8K | 9/28/2023 |
| Chen Schor | ▲ Buy | Open Market | 5,500 | $8K | 9/28/2023 |
| Steve Dubin | ▲ Buy | Open Market | 5,000 | $12K | 6/30/2023 |
| Carl L. Gordon | ▲ Buy | Open Market | 125,000 | $261K | 6/27/2023 |
| Carl L. Gordon | ▲ Buy | Open Market | 250,000 | $522K | 6/27/2023 |
| Carl L. Gordon | ▲ Buy | Open Market | 442,000 | $924K | 6/27/2023 |
| Carl L. Gordon | ▲ Buy | Open Market | 58,000 | $121K | 6/27/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 125,000 | $261K | 6/27/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 250,000 | $522K | 6/27/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 442,000 | $924K | 6/27/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 58,000 | $121K | 6/27/2023 |
| Jeffrey Chodakewitz | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Sanna Bastiano | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Michael Kauffman | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Jakobovits Aya | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Carl L. Gordon | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Steve Dubin | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Andrew Sinclair | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 |
| Don Healey | ▼ Sell | Open Market | 4,533 | $34K | 2/15/2023 |
| Don Healey | ▼ Sell | Open Market | 10,467 | $83K | 2/10/2023 |
| Galimi Francesco | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 |
| Chen Schor | ▲ Buy | Grant | 85,500 | $0 | 1/24/2023 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 |
| Don Healey | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 |
| Blake Aftab | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 |
| Blake Aftab | ▼ Sell | Open Market | 6,967 | $146K | 11/10/2022 |
| Chen Schor | ▼ Sell | Open Market | 9,955 | $209K | 11/10/2022 |
| Chen Schor | ▼ Sell | Open Market | 30,000 | $602K | 11/10/2022 |
| Chen Schor | ▼ Sell | Open Market | 30,000 | $571K | 11/7/2022 |
| Chen Schor | ▼ Sell | Open Market | 24,813 | $448K | 11/3/2022 |
| Chen Schor | ▼ Sell | Open Market | 500 | $9K | 11/2/2022 |
| Blake Aftab | ▼ Sell | Open Market | 8,067 | $131K | 10/19/2022 |
| Blake Aftab | ▼ Sell | Tax Withholding | 7,933 | $126K | 10/13/2022 |
| Blake Aftab | ▲ Buy | Option Exercise | 3,388 | $25K | 10/12/2022 |
| Blake Aftab | ▼ Sell | Open Market | 1,646 | $25K | 10/12/2022 |
| Chen Schor | ▼ Sell | Tax Withholding | 21,288 | $303K | 10/4/2022 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 7,096 | $101K | 10/4/2022 |
| Don Healey | ▼ Sell | Tax Withholding | 7,933 | $113K | 10/4/2022 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 7,933 | $113K | 10/4/2022 |
| Chen Schor | ▼ Sell | Open Market | 952 | $17K | 9/14/2022 |
| Chen Schor | ▼ Sell | Open Market | 3,371 | $61K | 9/13/2022 |
| Chen Schor | ▼ Sell | Open Market | 66,747 | $1.1M | 9/12/2022 |
| Chen Schor | ▼ Sell | Open Market | 200 | $4K | 9/12/2022 |
| Chen Schor | ▼ Sell | Open Market | 8,094 | $134K | 9/9/2022 |
| Chen Schor | ▲ Buy | Grant | 48,000 | $0 | 8/4/2022 |
| Chen Schor | ▼ Sell | Tax Withholding | 21,288 | $389K | 8/4/2022 |
| Galimi Francesco | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 |
| Blake Aftab | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 |
| Blake Aftab | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 4,696 | $86K | 8/4/2022 |
| Don Healey | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 |
| Don Healey | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 |
| Blake Aftab | ▼ Sell | Open Market | 6,968 | $125K | 8/3/2022 |
| Blake Aftab | ▼ Sell | Open Market | 6,968 | $116K | 8/1/2022 |
| Chen Schor | ▼ Sell | Gift | 53,424 | $0 | 7/6/2022 |
| Chen Schor | ▼ Sell | Gift | 53,424 | $0 | 7/6/2022 |
| Blake Aftab | ▼ Sell | Open Market | 1,363 | $20K | 7/5/2022 |
| Galimi Francesco | ▲ Buy | Option Exercise | 6,036 | $80K | 4/4/2022 |
| Galimi Francesco | ▼ Sell | Open Market | 6,036 | $127K | 4/4/2022 |
| Galimi Francesco | ▲ Buy | Option Exercise | 168 | $1K | 4/4/2022 |
| Galimi Francesco | ▼ Sell | Open Market | 168 | $4K | 4/4/2022 |
| Galimi Francesco | ▲ Buy | Option Exercise | 1,775 | $30K | 4/4/2022 |
| Galimi Francesco | ▼ Sell | Open Market | 1,775 | $37K | 4/4/2022 |
| Galimi Francesco | ▲ Buy | Option Exercise | 7,621 | $45K | 4/1/2022 |
| Galimi Francesco | ▼ Sell | Open Market | 7,621 | $160K | 4/1/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $28K | 3/9/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $28K | 3/9/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $30K | 2/16/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $30K | 2/16/2022 |
| Don Healey | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 |
| Don Healey | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 |
| Blake Aftab | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 |
| Blake Aftab | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 |
| Galimi Francesco | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 4,696 | $67K | 2/14/2022 |
| Chen Schor | ▲ Buy | Grant | 48,000 | $0 | 2/14/2022 |
| Chen Schor | ▼ Sell | Tax Withholding | 21,288 | $304K | 2/14/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 4,000 | $56K | 2/9/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 4,000 | $56K | 2/9/2022 |
| Galimi Francesco | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 |
| Galimi Francesco | ▼ Sell | Tax Withholding | 5,533 | $65K | 1/28/2022 |
| Don Healey | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 |
| Don Healey | ▼ Sell | Tax Withholding | 5,533 | $65K | 1/28/2022 |
| Blake Aftab | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 |
| Blake Aftab | ▼ Sell | Tax Withholding | 5,564 | $65K | 1/28/2022 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 |
| Brian Nicholas Harvey | ▼ Sell | Tax Withholding | 4,696 | $55K | 1/28/2022 |
| Chen Schor | ▲ Buy | Grant | 48,000 | $0 | 1/28/2022 |
| Chen Schor | ▼ Sell | Tax Withholding | 21,288 | $249K | 1/28/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $34K | 1/5/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 2,000 | $34K | 1/5/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 6,000 | $108K | 1/3/2022 |
| Jakobovits Aya | ▼ Sell | Open Market | 6,000 | $108K | 1/3/2022 |
| Carl L. Gordon | ▲ Buy | Grant | 214,285 | $3.0M | 12/10/2021 |
| ORBIMED ADVISORS LLC | ▲ Buy | Grant | 214,285 | $3.0M | 12/10/2021 |
| Andrew Sinclair | ▲ Buy | Open Market | 500,000 | $7.0M | 12/8/2021 |
| Blake Aftab | ▲ Buy | Grant | 80,000 | $0 | 10/12/2021 |
| Chen Schor | ▲ Buy | Grant | 240,000 | $0 | 10/1/2021 |
| Don Healey | ▲ Buy | Grant | 80,000 | $0 | 10/1/2021 |
| Galimi Francesco | ▲ Buy | Grant | 80,000 | $0 | 10/1/2021 |
| Brian Nicholas Harvey | ▲ Buy | Grant | 80,000 | $0 | 10/1/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.